Dimensional Fund Advisors LP Has $45.29 Million Stock Position in Evolent Health, Inc. (NYSE:EVH)

Dimensional Fund Advisors LP boosted its position in Evolent Health, Inc. (NYSE:EVH) by 5.4% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 2,368,255 shares of the technology company’s stock after purchasing an additional 121,770 shares during the period. Dimensional Fund Advisors LP owned about 2.04% of Evolent Health worth $45,286,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. ICA Group Wealth Management LLC bought a new position in Evolent Health in the 4th quarter valued at about $33,000. Headlands Technologies LLC bought a new position in Evolent Health in the 1st quarter valued at about $46,000. NBC Securities Inc. raised its holdings in Evolent Health by 16.6% in the 1st quarter. NBC Securities Inc. now owns 2,461 shares of the technology company’s stock valued at $81,000 after acquiring an additional 350 shares during the period. Quest Partners LLC bought a new position in Evolent Health in the 2nd quarter valued at about $87,000. Finally, Banque Cantonale Vaudoise bought a new position in shares of Evolent Health during the first quarter worth approximately $88,000.

Insider Transactions at Evolent Health

In related news, General Counsel Jonathan Weinberg sold 42,140 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total value of $1,314,768.00. Following the transaction, the general counsel now owns 167,027 shares in the company, valued at $5,211,242.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, General Counsel Jonathan Weinberg sold 42,140 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $31.20, for a total value of $1,314,768.00. Following the transaction, the general counsel now owns 167,027 shares in the company, valued at $5,211,242.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, COO Emily Ann Rafferty sold 8,861 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $30.00, for a total transaction of $265,830.00. Following the completion of the transaction, the chief operating officer now owns 63,408 shares in the company, valued at approximately $1,902,240. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 307,291 shares of company stock worth $9,290,385. Company insiders own 1.60% of the company’s stock.

Evolent Health Stock Performance

Shares of Evolent Health stock opened at $29.30 on Monday. Evolent Health, Inc. has a fifty-two week low of $17.98 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.08 and a quick ratio of 1.08. The firm has a market capitalization of $3.41 billion, a P/E ratio of -23.44 and a beta of 1.57. The company’s 50 day moving average price is $27.54 and its two-hundred day moving average price is $26.19.

Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.21 by $0.09. The company had revenue of $647.10 million for the quarter, compared to analyst estimates of $636.46 million. Evolent Health had a negative net margin of 3.16% and a positive return on equity of 8.47%. Evolent Health’s revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.06 earnings per share. On average, equities analysts forecast that Evolent Health, Inc. will post 0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on EVH shares. Truist Financial reaffirmed a “buy” rating and set a $33.00 target price on shares of Evolent Health in a report on Tuesday, August 27th. Stephens reaffirmed an “overweight” rating and set a $42.00 target price on shares of Evolent Health in a report on Tuesday, July 30th. JMP Securities lowered their target price on shares of Evolent Health from $34.00 to $31.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. JPMorgan Chase & Co. raised their target price on shares of Evolent Health from $36.00 to $45.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Evolent Health in a report on Monday, August 26th. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Evolent Health has a consensus rating of “Moderate Buy” and an average target price of $40.40.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.